adverse events following immunization

Any untoward medical occurrence in a vaccine which follows immunization and may not necessarily have a causal relationship with the administration of the vaccine


Similar or alike

antibody titers

Clinical test to measure amount of antibody in person’s blood


Substance that induces an immune response, trigger production of antibodies

benefit-to-risk profile

Predicted benefits from the vaccine outweigh the predicted risk of adverse events


An additional vaccine to help sustain immunity


Capsule around the pathogen


Medications that reduce inflammation

diaphragmatic breathing

Take slow breath in the nose, breathing into lower abdomen *about 4 seconds
Hold breath for 1-2 seconds
Exhale slowly through the mouth *about 4 seconds


Efficacy is measured in controlled clinical trials, whereas effectiveness is measured once the vaccine is approved for use in the general population


Refers to complete and permanent worldwide reduction to zero new cases

entry-to-practice level competency

Minimum requirements for a nurse to enter into practice


Reduction to zero (or a very low defined target rate) of new cases in specified regions

Food and Drugs Act and Regulations

National safety standards for safety and nutritional quality

Good Clinical Practice (GCP)

International quality standards for the conduct of clinical trials defined by the International Conference for Harmonization

Good Laboratory Practice (GLP)

International practice standards that govern all aspects of laboratory data and ensure integrity of chemical pre-clinical safety testing

Good Manufacturing Practice (GMP)

A national system of standards to ensure that the vaccine production process uses acceptable quality materials, meets specifications consistently, each new lot has same characteristics of safety and efficacy, and is done in a licensed establishment


Time taken for the property to reduce by half

herd immunity

The resistance to the spread of a contagious disease in a sufficiently high proportion of the population, particularly through vaccination

heuristic thinking

Shortcuts or quick reactive thinking

immunosuppressant agents

Medications that reduce or suppress the strength of a body’s immune system response (e.g., antirejection drugs following organ transplant)

population health approach

Aims to optimize the health status of a whole population (as opposed to specific individuals) and reduce health inequities among sub-populations

post-marketing period

Time after vaccine has been marketed to general population for use

resource-constrained environments

Workplaces facing limited staff, equipment or other financial limitations


Looking back on past events or relying on recall


Laying position/flat on back


The study of congenital abnormalities during development

the most responsible provider

Doctor or nurse practitioner

vaccine life cycle

Refers to the various stages of vaccine development and delivery

vaccine safety signals

Information that indicates a potential link between a vaccine and an event previously unknown or incompletely documented, that could affect health


Icon for the Creative Commons Attribution-ShareAlike 4.0 International License

Vaccine Practice for Health Professionals: 1st Canadian Edition Copyright © by Oona St-Amant; Jennifer Lapum; Vinita Dubey; Karen Beckermann; Che-Sheu Huang; Carly Weeks; Kate Leslie; and Kim English is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License, except where otherwise noted.

Share This Book